Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intellance 1: ABT-414 with chemoradiation and adjuvant temozolomide in newly diagnosed EGFR-amplified glioblastoma
NL-OMON47442Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing ABT-414 + radiotherapy + temozolomide with Placebo + radiotherapy + temozolomide (2 arms). Primary endpoint: Overall survival. Started May 2016; status: active, not recruiting.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON47442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47442.